An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. Researchers report that one dose of their vaccine candidate elicited large increases in RSV-neutralizing antibodies that were sustained for several months.